ONCT 216
Alternative Names: I-036; SPH-8216; TK-216Latest Information Update: 28 Mar 2023
At a glance
- Originator Tokalas, Inc.
- Developer Oncternal Therapeutics, Inc.; Shanghai Pharmaceuticals Holding
- Class Antineoplastics; Chlorinated hydrocarbons; Cyclopropanes; Indoles; Small molecules
- Mechanism of Action Proto-oncogene protein c-ets inhibitors; Proto-oncogene protein c-fli-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ewing's sarcoma
- Preclinical Diffuse large B cell lymphoma; Prostate cancer
- No development reported Acute myeloid leukaemia; Glioblastoma
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Parenteral)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA (Parenteral)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Glioblastoma in USA (Parenteral)